Brief: Lung Cancer Patient In Lantern Pharma’s Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years
16/06/2025 13:33
June 16 (Reuters) - Lantern Pharma Inc LTRN.O: LUNG CANCER PATIENT IN LANTERN PHARMA’S HARMONIC TRIAL SHOWS DURABLE COMPLETE RESPONSE IN TARGET CANCER LESIONS WITH SURVIVAL CONTINUING FOR NEARLY TWO YEARS LANTERN PHARMA INC - NO SIGNIFICANT ADVERSE DRUG REACTIONS OVER 21 CYCLES OF TREATMENT LANTERN PHARMA: ANTICIPATES ADDITIONAL DATA UPDATE FROM RANDOMIZED EXPANSION PHASE IN H2 2025 Source text: ID:nBwcclSta Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview